March 14, 2024

Y-mAbs Therapeutics Announces Resignation of Chief Financial Officer

March 04, 2024

Y-mAbs Appoints Oncology Executive Mary Tagliaferri, M.D. to its Board of Directors

February 29, 2024

Y-mAbs Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Developments

February 16, 2024

Y-mAbs to Announce Fourth Quarter and Full Year 2023 Financial and Operating Results on February 29, 2024

January 02, 2024

Y-mAbs Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference

December 13, 2023

Y-mAbs Therapeutics Added to the NASDAQ Biotechnology Index

November 13, 2023

Y-mAbs Reports Third Quarter 2023 Financial Results and Recent Corporate Developments

October 31, 2023

Y-mAbs to Announce Third Quarter 2023 Financial and Operating Results on November 13, 2023

October 18, 2023

Y-mAbs Names Michael Rossi as President and Chief Executive Officer and Director

October 17, 2023

Y-mAbs Therapeutics Announces U.S. FDA Clearance of Investigational New Drug Application for CD38-SADA

October 16, 2023

Y-mAbs Announces Publication in Cancers

September 21, 2023

Y-mAbs Announces Data to be Presented at the 55th Congress of the International Society of Pediatric Oncology

September 06, 2023

Y-mAbs to Participate at Upcoming Investor Conferences in September

August 10, 2023

Y-mAbs Reports Second Quarter 2023 Financial Results and Recent Corporate Developments

August 02, 2023

Y-mAbs to Participate at Upcoming Investor Conferences

August 01, 2023

Y-mAbs to Announce Second Quarter 2023 Financial and Operating Results on August 10, 2023

May 26, 2023

Y-mAbs Announces Presentation of Naxitamab Data at ASCO

May 26, 2023

Y-mAbs Announces Presentation of GD2-SADA Study at ASCO

May 23, 2023

Y-mAbs’ DANYELZA® (naxitamab-gqgk) for the Treatment of High-Risk Neuroblastoma approved in Brazil

May 08, 2023

Y-mAbs Reports First Quarter 2023 Financial Results and Recent Corporate Developments and Updates 2023 Financial Guidance

April 28, 2023

Y-mAbs to Announce First Quarter 2023 Financial and Operating Results on May 8, 2023

April 18, 2023

Y-mAbs Announces Presentation of Naxitamab data at AACR

April 05, 2023

Y-mAbs Announces First Patient Dosed in Phase 1 Clinical Trial of GD2-SADA

March 30, 2023

Y-mAbs Reports Fourth Quarter and Full-Year 2022 Financial Results and Recent Corporate Developments

March 21, 2023

Y-mAbs to Announce 2022 Financial and Operating Results on March 30, 2023

February 02, 2023

Y-mAbs and the European Medicines Agency Reach Agreement on the Pediatric Investigation Plan for Naxitamab

January 04, 2023

Y-mAbs Announces Restructuring Plan and Provides Financial Outlook Following Complete Response Letter from FDA

January 03, 2023

Y-mAbs Therapeutics to Present at 41st Annual J.P. Morgan Healthcare Conference

December 21, 2022

Y-mAbs Announces Partnership Regarding Early Access Program for DANYELZA (naxitamab-gqgk) in Europe

December 16, 2022

The CHMP has Adopted a Negative Opinion for Omburtamab for the Treatment of CNS/LM Metastasis from Neuroblastoma in Europe

December 14, 2022

Y-mAbs Announces Pipeline Update

December 08, 2022

Y-mAbs’ DANYELZA® (naxitamab-gqgk) for the Treatment of High-Risk Neuroblastoma Approved in China

December 06, 2022

Y-mAbs to Host Annual Research and Development Day in New York

December 01, 2022

Y-mAbs Announces Complete Response Letter for Omburtamab Biologics License Application

November 07, 2022

Y-mAbs Reports Third Quarter 2022 Financial Results and Recent Corporate Developments

November 02, 2022

Y-mAbs to Announce Third Quarter 2022 Financial and Operating Results on November 7, 2022

October 28, 2022

Y-mAbs Announces Outcome of FDA Advisory Committee Meeting on Omburtamab

October 03, 2022

Y-mAbs Announces Pivotal Data for Omburtamab

September 26, 2022

Y-mAbs Announces Regulatory Filing for DANYELZA® (naxitamab-gqgk) in Brazil

September 01, 2022

Y-mAbs Announces Scheduling of FDA Advisory Committee Meeting for Omburtamab

August 30, 2022

Y-mAbs and Takeda Announces Marketing Authorization in Israel for DANYELZA® (naxitamab-gqgk) for Neuroblastoma

August 08, 2022

Y-mAbs Announces Second Quarter Financial Results and Recent Corporate Developments

August 02, 2022

Y-mAbs to Announce Second Quarter 2022 Financial and Operating Results on August 8, 2022

July 12, 2022

Y-mAbs’ Announces Clearance of IND for GD2-SADA

May 31, 2022

Y-mAbs Announces FDA Acceptance of Biologics License Application for OMBLASTYS® (omburtamab) for the Treatment of Neuroblastoma for Priority Review

May 26, 2022

Y-mAbs Announces Naxitamab Chemoimmunotherapy Investigational Trial for High-Risk Neuroblastoma Meets Primary Endpoint

May 09, 2022

Y-mAbs Announces First Quarter Financial Results and Recent Corporate Developments

May 03, 2022

Y-mAbs to Announce First Quarter 2022 Financial and Operating Results on May 9, 2022

April 27, 2022

Y-mAbs Announces Executive Management Changes and Provides 2022 Revenue Guidance and Financial Update

April 08, 2022

Y-mAbs Announces Presentation of SADA Technology at AACR